Cited by 48Nanoplatforms for cancer theranosticsPhotodynamic Therapy Research StudiesPhagocytosis and Immune Regulation

CD47-targeted bismuth selenide nanoparticles actualize improved photothermal therapy by increasing macrophage phagocytosis of cancer cells

Guo, Zhaoming, Liu, Ye, Zhou, Hao, Zheng, Kun, Wang, Dong, Jia, Mingli, Xu, Pengcheng, Ma, Kun +2 more·2019·Colloids and Surfaces B: Biointerfaces

Abstract

CD47, a transmembrane protein overexpressed in most tumors, limits macrophage phagocytosis by interacting with macrophage signal-regulated protein α (SIRPα). In this study, we have developed CD47-targeted bismuth selenide nanoparticles (Ab-PEG-Bi 2 Se 3) that increase phagocytosis of cancer cells by macrophages to actualize improved photothermal therapy (PTT). The functionalized nanoparticles were constructed by conjugating anti-CD47 antibody (Ab) to PEGylated bismuth selenide nanoparticles (PEG-Bi 2 Se 3). The anti-CD47 antibody modified on the nanoparticles enhanced the phagocytic activity of macrophages toward tumor cells by specifically blocking the crosstalk between CD47 and SIRPα. Meanwhile, Ab-PEG-Bi 2 Se 3 showed excellent photothermal performance including strong near infrared (NIR) absorbance, high photothermal conversion efficiency and photostability, and exhibited outstanding in vitro PTT effect under NIR laser irradiation. In vivo therapeutic experiments revealed that this CD47-targeted PTT nanoagent, with the assistance of enhanced macrophage phagocytosis, achieved the goal of tumor eradication. Besides, toxicity studies confirmed that Ab-PEG-Bi 2 Se 3 had good biocompatibility. In conclusion, Ab-PEG-Bi 2 Se 3 may serve as an efficient PTT platform in combination with macrophage-mediated immunotherapy to improve antitumor efficacy.

Integrity signals

Registry

Crossref · 10.1016/j.colsurfb.2019.110546

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A variety of tumor cell surface markers such as CD44, CD47, CD20, CD147, CD31 have been identified as effective targets for specific and selective anti-tumor therapy.

    “In addition to the above specific ligand modifications, a variety of tumor cell surface markers such as CD44, CD47, CD20, CD147, CD31 have been identified as effective targets for specific and selective anti-tumor therapy.214–216”

    From Smart nanoparticles for cancer therapy (2023) · cites this paper as [216]

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Guo, Z., Liu, Y., Zhou, H., Zheng, K., Wang, D., Jia, M., Xu, P., Ma, K., Cui, C., & Wang, L.
Affiliations
  • Dalian University of Technology (CN)
  • Inner Mongolia Medical University (CN)
Corresponding author
  • Guo, Zhaoming
  • Wang, Li
Venue
Colloids and Surfaces B: Biointerfaces
Publisher
Elsevier BV
Published
2019-12
Volume
184
Pages
110546
ISSN
0927-7765 (ISSN-L)
OpenAlex
W2977354137
Cited by
48
References
36
Citations by year
2026: 4 · 2025: 11 · 2024: 2 · 2023: 8 · 2022: 7 · 2021: 11 · 2020: 5
FWCI
2.03
Type
journal article
Language
en
Open access
closed
Locations
  • Colloids and Surfaces B Biointerfaces (publishedVersion)
  • PubMed (publishedVersion)
Funders
  • Fundamental Research Funds for the Central Universities
  • Natural Science Foundation of Liaoning Province
  • National Natural Science Foundation of China
Topics
  • Physical Sciences › Engineering › Biomedical Engineering › Nanoplatforms for cancer theranostics
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Photodynamic Therapy Research Studies
  • Life Sciences › Immunology and Microbiology › Immunology › Phagocytosis and Immune Regulation
Keywords
CD47, photothermal therapy, macrophage phagocytosis, SIRPα, anti-CD47 antibody, PEGylation, near-infrared absorption, tumor targeting, antitumor efficacy, nanoparticle toxicity
MeSH terms
A549 Cells, Animals, Antineoplastic Agents, Bismuth, Drug Screening Assays, Antitumor, Female, Humans, Infrared Rays, Macrophages, Mammary Neoplasms, Experimental, Mice, Inbred BALB C, Particle Size, Phagocytosis, Photochemotherapy, Surface Properties, Tumor Cells, Cultured, Molecular Structure, Organoselenium Compounds, Selenium Compounds, Cell Proliferation, Mice, CD47 Antigen, Nanoparticles

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review